Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Research

Background:

• High tumor mutational burden (TMB) correlates with neoantigen load and response to immune checkpoint inhibitors.
• Pembrolizumab, an anti-PD-1 therapy, received FDA approval for solid tumors with high TMB (>10 mutations/megabase) based on a Phase II study.
• This approval expanded treatment options for patients likely to benefit from immunotherapy.

Purpose of the Study:

• To discuss the scientific rationale and utility of TMB as a predictive biomarker for immunotherapy response.
• To address the limitations and ongoing debate surrounding the predictive value of TMB.

Main Methods:

• Review of existing studies and clinical trial data.
• Analysis of the scientific basis for TMB as a predictive biomarker.
• Discussion of the clinical implications and limitations of TMB testing.

Main Results:

• TMB is associated with response to checkpoint blockade therapies.
• FDA approval of pembrolizumab for high TMB solid tumors marked a significant advancement.
• Concerns and debates exist regarding the predictive accuracy and broad applicability of TMB.

Conclusions:

• TMB serves as a valuable biomarker for predicting immunotherapy response in certain solid tumors.
• Further research and critical evaluation are necessary to fully understand TMB's utility and limitations.
• The role of TMB in guiding treatment decisions requires careful consideration within the broader clinical context.